You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Oncolytic virus-mediated target delivery of a therapeutic antibody fragment in glioblastoma

    SBC: Oncosynergy, Inc.            Topic: 102

    PROJECT SUMMARY More thanpatients are diagnosed each year with glioblastomathe most common primary brain tumorCurrent treatments are inadequate and there have been no major therapeutic breakthroughs in decadesHencethere is an urgent need to develop novel strategies to address this devastating diseaseHoweverdevelopment of an effective treatment for glioblastoma is severely hampered bythe blood brai ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. APPSPIRE: expanding the reach of an innovative tobacco control program for youth

    SBC: Radiant Creative Group, LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): Mobile phone technology offers a variety of opportunities for innovative approaches to health communication and intervention. These opportunities have been amplified by the emergence of next-generation smartphone devices that are capable of rich multimedia and sophisticated interactivity. Smartphone-based programs can be integrated seamlessly into a user's ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. C/EBP-beta PEPTIDES FOR THE TREATMENT OF LIVER INJURY AND FIBROSIS

    SBC: XFIBRA, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Activation of hepatic stellate cells (HSC) is responsible for the development of liver fibrosis in chronic liver diseases of all causes and remarkably, HSC clearance by apoptosis may allow recovery from liver injury andreversal of liver fibrosis. There is full agreement among liver fibrosis experts that inhibiting o reversing HS activation (the therapeutic targ ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.

    SBC: Oncoimmune Inc            Topic: 100

    Project Summary AbstractThe recent rapid expansion of genomic data greatly contributes to the understanding of disease development and progressionTo translate these genetic discoveries into clinical applicationswe need to develop therapeutic platforms that can specifically modulate the expression of disease related genes in vivoSmall RNAssuch as microRNAs and siRNAs function in messenger RNA silen ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Contractile Hydrogel Dressing for Primary Wound Closure

    SBC: LYNNTECH INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Acute and chronic wounds such as diabetic foot ulcers represent a major area of medical concern. With roughly 27 million patients suffering from these types of partial thickness wounds, representing substantial billions in medical expenses, a means to rapidly close such acute and chronic wounds with minimal medical staff involvement would be a major new bre ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Small Molecule targeting of NADPH oxidase in neutrophils

    SBC: P2D, INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are characterized by a rapid and severe respiratory failure, arising after clinical events including major surgery, trauma, multiple transfusions and sepsis. ALI/ARDS have an associated mortality of 40-80% and current pharmacological modalities have been unsuccessful in decreasing mortality. ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Stimuli Responsive Topical Gels for Mechanically Assisted Wound Debridement

    SBC: LYNNTECH INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Debridement of dead, damaged and/or infected tissue from thermal burn wounds and a certain subset of ischemic and necrotic diabetic foot wounds is a commonly utilized wound preparation modality before the application of fillers, dressings or grafts. The existing wound debridement techniques have serious issues such as invasiveness and impreciseness, painful ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. In vivo expansion of human hepatocytes in Fah-/-Rag-/-Il2rg-/- mice

    SBC: Yecuris Corporation            Topic: NCRR

    DESCRIPTION (provided by applicant): The liver is the site of many metabolic processes, including metabolism of xenobiotics such as pharmaceutical compounds. Drug metabolism is highly species specific and can vary significantly between individuals of the same species. To date no reliable experimental system capable of predicting the human-specific metabolic conversion of candidate small molecules ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Pulse Oximeter for Newborn Screening

    SBC: INTELLIGENT OPTICAL SYSTEMS, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): Congenital heart diseases (CHD) are the most common serious congenital anomalies and the leading cause of death due to birth defects. Clinical practice relying on physical examination of the newborn before discharge from the nursery often misses newborns with critical CHD (CCHD), which can lead to death or long-term morbidities. Using pulse oximetry (PO) can im ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. High-Throughput Assay for Profiling Alternative Splicing and Splicing Regulators

    SBC: Biospyder Technologies, Inc.            Topic: 172

    SummaryThis Phase I program will develop TempO Splicea highly multiplexed targeted sequencing assay monitoring RNA Binding ProteinRBPsplicing expression and alternatively splicedASmRNA representatives of coregulated splicing modulesa novel variation of the TempO Seqassay used for high throughput screeningdesigned to address the hypothesis that it is possible to provide a surrogate assay of the who ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government